Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Elevated levels of ornithine decarboxylase cooperate with Raf/ERK activation to convert normal keratinocytes into invasive malignant cells

Abstract

Ornithine decarboxylase (ODC) overexpression coupled with activated Ras is fully sufficient to oncogenically transform primary keratinocytes. To determine the Ras effector pathways that represent the minimal essential contribution to full oncogenic transformation in this context, we evaluated the cooperativity of different Ras effector mutants with overexpressed ODC in an in vivo tracheal xenotransplantation assay for epithelial cell invasiveness. Primary keratinocytes, isolated from either K6/ODC transgenic mouse skin (expressing increased ODC) or from normal littermate skin were infected with retrovirus producing an activated RasV12 or partial loss-of-function effector mutants of RasV12 that selectively induce only the Raf/ERK, RalGDS, or the PI3-kinase signaling pathway. Whereas keratinocytes expressing a fully activated RasV12 are not invasive in tracheal xenotransplants, ODC-overexpressing keratinocytes acquire an invasive phenotype with additional expression of either RasV12 or activation of the Raf/ERK pathway. Independent of a mutated ras, elevated levels of ODC activate the Akt/mTOR signaling pathway as well as the Rho/Rac pathway in primary keratinocytes. Thus, Raf/ERK signaling is sufficient to cooperate with increased ODC activity in the conversion of normal keratinocytes to invasive cells. In order to promote invasiveness in keratinocytes, elevated levels of ODC may cooperate with Raf/ERK via activation of the Akt and Rho/Rac signaling pathway.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  • Ahmad N, Gilliam AC, Katiyar SK, O'Brien TG, Mukhtar H . (2001). Am J Pathol 159: 885–892.

  • Bedogni B, O'Neill MS, Welford SM, Bouley DM, Giaccia AJ, Denko NC et al. (2004). Cancer Res 64: 2552–2560.

  • Benard V, Bohl BP, Bokoch GM . (1999). J Biol Chem 274: 13198–13204.

  • Benitah SA, Valeron PF, van Aelst L, Marshall CJ, Lacal JC . (2004). Biochim Biophys Acta 1705: 121–132.

  • Bjornsti MA, Houghton PJ . (2004). Nat Rev Cancer 4: 335–348.

  • Boettner B, Van Aelst L . (2002). Gene 286: 155–174.

  • Burridge K, Wennerberg K . (2004). Cell 116: 167–179.

  • Campbell PM, Der CJ . (2004). Semin Cancer Biol 14: 105–114.

  • Cantley LC, Neel BG . (1999). Proc Natl Acad Sci USA 96: 4240–4245.

  • Collette J, Ulku AS, Der CJ, Jones A, Erickson AH . (2004). Int J Cancer 112: 190–199.

  • Feith DJ, Bol DK, Carboni JM, Lynch MJ, Sass-Kuhn S, Shoop PL et al. (2005). Cancer Res 65: 572–578.

  • Feith DJ, Shantz LM, Pegg AE . (2001). Cancer Res 61: 6073–6081.

  • Gilmour SK, Birchler M, Smith MK, Rayca K, Mostochuk J . (1999). Cell Growth Differ 10: 739–748.

  • Gilmour SK, Teti KA, Wu KQ, Morris RJ . (2001). J Invest Dermatol 117: 1674–1676.

  • Hamad NM, Elconin JH, Karnoub AE, Bai W, Rich JN, Abraham RT et al. (2002). Genes Dev 16: 2045–2057.

  • Hennings H, Michael D, Cheng C, Steinert P, Holbrook K, Yuspa SH . (1980). Cell 19: 245–254.

  • Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O et al. (1999). Oncogene 18: 813–822.

  • Jaffer ZM, Chernoff J . (2004). J Biol Chem 279: 35123–35126.

  • Keely PJ, Westwick JK, Whitehead IP, Der CJ, Parise LV . (1997). Nature 390: 632–636.

  • Kuriyama M, Harada N, Kuroda S, Yamamoto T, Nakafuku M, Iwamatsu A et al. (1996). J Biol Chem 271: 607–610.

  • Lan L, Hayes CS, Laury-Kleintop L, Gilmour S . (2005). J Invest Dermatol 124: 602–614.

  • Lan L, Trempus C, Gilmour SK . (2000). Cancer Res 60: 5696–5703.

  • Lin TA, Kong X, Haystead TA, Pause A, Belsham G, Sonenberg N et al. (1994). Science 266: 653–656.

  • Magee T, Marshall C . (1999). Cell 98: 9–12.

  • McFarlin DR, Lindstrom MJ, Gould MN . (2003). Carcinogenesis 24: 99–105.

  • Megosh L, Gilmour SK, Rosson D, Soler AP, Blessing M, Sawicki JA et al. (1995). Cancer Res 55: 4205–4209.

  • O'Brien TG, Megosh LC, Gilliard G, Soler AP . (1997). Cancer Res 57: 2630–2637.

  • O'Brien TG, Simsiman RC, Boutwell RK . (1975). Cancer Res 35: 1662–1670.

  • Oldham SM, Clark GJ, Gangarosa LM, Coffey Jr RJ, Der CJ . (1996). Proc Natl Acad Sci USA 93: 6924–6928.

  • Pegg AE . (1988). Cancer Res 48: 759–774.

  • Ray RM, Bhattacharya S, Johnson LR . (2005). J Biol Chem 280: 31091–31100.

  • Ray RM, McCormack SA, Covington C, Viar MJ, Zheng Y, Johnson LR . (2003). J Biol Chem 278: 13039–13046.

  • Ray RM, Patel A, Viar MJ, McCormack SA, Zheng Y, Tigyi G et al. (2002). Gastroenterology 123: 196–205.

  • Ren XD, Kiosses WB, Schwartz MA . (1999). EMBO J 18: 578–585.

  • Ridley AJ, Comoglio PM, Hall A . (1995). Mol Cell Biol 15: 1110–1122.

  • Ridley AJ, Hall A . (1992). Cell 70: 389–399.

  • Ridley AJ, Paterson HF, Johnston CL, Diekmann D, Hall A . (1992). Cell 70: 401–410.

  • Rodriguez-Viciana P, Warne PH, Khwaja A, Marte BM, Pappin D, Das P et al. (1997). Cell 89: 457–467.

  • Roop DR, Lowy DR, Tambourin PE, Strickland J, Harper JR, Balaschak M et al. (1986). Nature 323: 822–824.

  • Rottner K, Hall A, Small JV . (1999). Curr Biol 9: 640–648.

  • Sahai E, Olson MF, Marshall CJ . (2001). EMBO J 20: 755–766.

  • Sander EE, van Delft S, ten Klooster JP, Reid T, van der Kammen RA, Michiels F et al. (1998). J Cell Biol 143: 1385–1398.

  • Scholl FA, Dumesic PA, Khavari PA . (2004). Cancer Res 64: 6035–6040.

  • Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW . (1997). Cell 88: 593–602.

  • Settleman J, Narasimhan V, Foster LC, Weinberg RA . (1992). Cell 69: 539–549.

  • Shantz LM . (2004). Biochem J 377: 257–264.

  • Shantz LM, Pegg AE . (1998). Cancer Res 58: 2748–2753.

  • Shields JM, Pruitt K, McFall A, Shaub A, Der CJ . (2000). Trends Cell Biol 10: 147–154.

  • Sistonen L, Keski-Oja J, Ulmanen I, Holtta E, Wikgren BJ, Alitalo K . (1987). Exp Cell Res 168: 518–530.

  • Smith MK, Goral MA, Wright JH, Matrisian LM, Morris RJ, Klein-Szanto AJP et al. (1997). Cancer Res 57: 2104–2108.

  • Smith MK, Trempus CS, Gilmour SK . (1998). Carcinogenesis 19: 1409–1415.

  • Strugill TW, Ray LB, Erikson E, Maller JL . (1988). Nature 334: 715–718.

  • Sturge J, Hamelin J, Jones GE . (2002). J Cell Sci 115: 699–711.

  • Tabor CW, Tabor H . (1984). Ann Rev Biochem 53: 749–790.

  • Takigawa M, Verma AK, Simsiman RC, Boutwell RK . (1983). Cancer Res 43: 3732–3738.

  • Tang X, Kim AL, Feith DJ, Pegg AE, Russo J, Zhang H et al. (2004). J Clin Invest 113: 867–875.

  • Tarutani M, Cai T, Dajee M, Khavari PA . (2003). Cancer Res 63: 319–323.

  • Ulku AS, Schafer R, Der CJ . (2003). Mol Cancer Res 1: 1077–1088.

  • Van Aelst L, D'Souza-Schorey C . (1997). Genes Dev 11: 2295–2322.

  • Vial E, Sahai E, Marshall CJ . (2003). Cancer Cell 4: 67–79.

  • Vivanco I, Sawyers CL . (2002). Nat Rev Cancer 2: 489–501.

  • Waskiewicz AJ, Flynn AF, Proud CG, Cooper JA . (1997). EMBO J 16: 1909–1920.

  • Webb CP, Van Aelst L, Wigler MH, Woude GF . (1998). Proc Natl Acad Sci USA 95: 8773–8778.

  • Weeks CE, Hermann AL, Nelson FR, Slaga TS . (1982). Proc Natl Acad Sci USA 79: 6028–6032.

  • White MA, Nicolette C, Minden A, Polverino A, Van Aelst L, Karin M et al. (1995). Cell 80: 533–541.

  • Yuspa SH, Harris CC . (1974). Exp Cell Res 86: 95–105.

  • Zohn IM, Campbell SL, Khosravi-Far R, Rossman KL, Der CJ . (1998). Oncogene 17: 1415–1438.

  • Zondag GC, Evers EE, ten Klooster JP, Janssen L, van der Kammen RA, Collard JG . (2000). J Cell Biol 149: 775–782.

Download references

Acknowledgements

We thank Drs Alex Muller and Cheryl Hobbs for valuable comments on the manuscript. We also thank Gwen Gilliard for histology assistance and Loretta Rossino for manuscript preparation. This work was supported by the NIH grant CA070739. This work was supported by Grant CA070739 to SKG from the National Cancer Institute.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to S K Gilmour.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hayes, C., DeFeo, K., Lan, L. et al. Elevated levels of ornithine decarboxylase cooperate with Raf/ERK activation to convert normal keratinocytes into invasive malignant cells. Oncogene 25, 1543–1553 (2006). https://doi.org/10.1038/sj.onc.1209198

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1209198

Keywords

This article is cited by

Search

Quick links